Disclaimer : The nephrology research discussed is based on preclinical or early investigational phase studies, including ongoing clinical research in kidney disease, renal protection, and related therapeutic pathways
7 The GLP-1 receptor (GLP-1R) is a G protein-coupled receptor that, when activated, triggers complex intracellular signaling cascades
In plain terms, Lilly posits that selectively targeting AMY1 reduces food intake & body weight with less taste avoidance (aka food still tastes good!) with less GI side effects that seem to be driven by the non-selective activity of cagrilintide on all these receptors
Concurrently, triple GIP, GLP1 and glucagon receptor agonists such as retatrutide are around the corner, which have impressive effects on glycaemic control, obesity and fatty liver disease [59, 60]